Tumor microenvironment-driven non-cell-autonomous resistance to antineoplastic treatment

Mol Cancer. 2019 Mar 30;18(1):69. doi: 10.1186/s12943-019-0992-4.

Abstract

Drug resistance is of great concern in cancer treatment because most effective drugs are limited by the development of resistance following some periods of therapeutic administration. The tumor microenvironment (TME), which includes various types of cells and extracellular components, mediates tumor progression and affects treatment efficacy. TME-mediated drug resistance is associated with tumor cells and their pericellular matrix. Noninherent-adaptive drug resistance refers to a non-cell-autonomous mechanism in which the resistance lies in the treatment process rather than genetic or epigenetic changes, and this mechanism is closely related to the TME. A new concept is therefore proposed in which tumor cell resistance to targeted therapy may be due to non-cell-autonomous mechanisms. However, knowledge of non-cell-autonomous mechanisms of resistance to different treatments is not comprehensive. In this review, we outlined TME factors and molecular events involved in the regulation of non-cell-autonomous resistance of cancer, summarized how the TME contributes to non-cell-autonomous drug resistance in different types of antineoplastic treatment, and discussed the novel strategies to investigate and overcome the non-cell-autonomous mechanism of cancer non-cell-autonomous resistance.

Keywords: Drug resistance; Non-cell-autonomous drug resistance; Tumor; Tumor microenvironment.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology
  • Drug Resistance, Neoplasm* / drug effects
  • Epigenesis, Genetic
  • Humans
  • Hydrogen-Ion Concentration
  • Neoplasms / drug therapy
  • Neoplasms / genetics
  • Neoplasms / metabolism*
  • Oxygen / metabolism
  • Signal Transduction / drug effects
  • Tumor Microenvironment* / drug effects

Substances

  • Antineoplastic Agents
  • Oxygen